2. Search Result
Search Result
Results for "

V

" in MedChemExpress (MCE) Product Catalog:

729

Inhibitors & Agonists

2

Screening Libraries

3

Fluorescent Dye

7

Biochemical Assay Reagents

82

Peptides

11

MCE Kits

22

Inhibitory Antibodies

82

Natural
Products

186

Recombinant Proteins

29

Isotope-Labeled Compounds

33

Antibodies

10

Click Chemistry

36

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112683
    V-9302
    15+ Cited Publications

    		 ASCT Cancer
    V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC50=9.6 μM) in HEK-293 cells .
    V-9302
  • HY-112683A
    V-9302 hydrochloride
    15+ Cited Publications

    		 ASCT Cancer
    V-9302 hydrochloride is a competitive antagonist of transmembrane glutamine flux. V-9302 hydrochloride selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 hydrochloride inhibits ASCT2-mediated glutamine uptake (IC50=9.6 µM) in HEK-293 cells .
    V-9302 hydrochloride
  • HY-143312A
    V-0219 hydrochloride

    		GLP Receptor Metabolic Disease
    V-0219 hydrochloride (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 hydrochloride can be used for obesity-associated diabetes research .
    V-0219 hydrochloride
  • HY-143312
    V-0219

    		GLP Receptor Metabolic Disease
    V-0219 (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 can be used for obesity-associated diabetes research .
    V-0219
  • HY-120337
    V-11-0711

    		Choline Kinase Cancer
    V-11-0711 is a potent and selective choline kinase alpha (ChoKα) inhibitor with an IC50 of 20 nM. V-11-0711 causes a reversible growth arrest in HeLa cells .
    V-11-0711
  • HY-W436428
    V-161

    		Na+/K+ ATPase Bacterial Infection
    V-161 is the orally active inhibitor for Na +-V-ATPase with an IC50 of 144 nM. V-161 inhibits Enterococcus hirae and Vancomycin-resistant Enterococcus faecium (VRE) under alkaline condition with MIC of 4 µg/mL and 4 µg/mL. V-161 inhibits colonization of VRE in mouse small intestine .
    V-161
  • HY-168742
    V1a/V2 antagonist 1

    		Vasopressin Receptor Neurological Disease
    V1a/V2 antagonist 1 (Compound 18j) is an orally active dual V1a and V2 receptor antagonist with high binding affinity for both receptors (Ki: 0.13 nM for hV1a, 0.53 nM for hV2 and 0.5 nM for mV1a; IC50: 2.2 nM for hV1a). V1a/V2 antagonist 1 inhibits Oxytocin (HY-17571)-induced scratching behavior in mice .
    V1a/V2 antagonist 1
  • HY-122143
    V-06-018

    		Bacterial Infection
    V-06-018 is a potent LasR antagonist with an IC50 value of 5.2 µM. V-06-018 can be used as chemical probes of quorum sensing (QS) in Pseudomonas aeruginosa .
    V-06-018
  • HY-163071
    V023-9340

    		FXR Metabolic Disease
    V023-9340 is a potent FXR inhibitor with IC50 of 4.27 μM that can be used in NASH (nonalcoholic steatohepatitis) research .
    V023-9340
  • HY-12914
    V116517

    		TRP Channel Neurological Disease Inflammation/Immunology
    V116517 is a potent, orally active transient receptor potential vanilloid (TRPV1) antagonist. V116517 shows potent activity in inhibiting both capsaicin (CAP)- and acid (pH 5)-induced currents in rat DRG neurons expressing native TRPV (IC50=423.2 nM for CAP; IC50=180.3 nM for acid). V116517 can be used for the research of pain .
    V116517
  • HY-162935
    V-ATPase-IN-1

    		Proton Pump Others
    V-ATPase-IN-1 (Compound 3b-03) is a Vacuolar-type H +-ATPases (V-ATPase) inhibitor (IC50 = 194.80 μM) that can effectively target the V-ATPase subunit A (Kd = 0.803 μM). V-ATPase-IN-1 exhibits insecticidal activity against M. separata (LC50 = 2.64 mM) and contributes to research in the development of chemical insecticides .
    V-ATPase-IN-1
  • HY-146272
    Vasopressin V2 receptor antagonist 1

    		Vasopressin Receptor Metabolic Disease
    Vasopressin V2 receptor antagonist 1 (Compound 4g) is a vasopressin V2 receptor (V2R) antagonist with a Ki of 3.8 nM. Vasopressin V2 receptor antagonist 1 can be used for autosomal dominant polycystic kidney disease (ADPKD) research .
    Vasopressin V2 receptor antagonist 1
  • HY-162394
    Vasopressin V2 receptor antagonist 2

    		Vasopressin Receptor Metabolic Disease
    Vasopressin V2 receptor antagonist 2 (Compound 33) is an antagonist of the arginine vasopressin V2 receptor (V2R) with a Ki value of 6.2 nM. Vasopressin V2 receptor antagonist 2 can effectively reduce cAMP levels, thereby inhibiting the growth of renal cysts[1].
    Vasopressin V2 receptor antagonist 2
  • HY-120374
    V-PYRRO/NO

    		Biochemical Assay Reagents Metabolic Disease
    V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.
    V-PYRRO/NO
  • HY-108504
    Co 102862

    V 102862

    		 Sodium Channel Neurological Disease
    Co 102862 (V 102862) is a potent, broad-spectrum, state-dependent Na + channel blocker. Co 102862 is also an orally active anticonvulsant .
    Co 102862
  • HY-162782A
    V–C6–Bg-PhCl TFA

    		Antibiotic Bacterial Infection
    V–C6–Bg-PhCl TFA (compound 5e) is a biguanide-vancomycin conjugate. V–C6–Bg-PhCl TFA has broad-spectrum antibacterial activity against both Gram-negative and Gram-positive bacteria .
    V–C6–Bg-PhCl TFA
  • HY-E70194
    Endoproteinase Glu-C

    V8 protease; Glu-C

    		 Ser/Thr Protease Others
    Endoproteinase GluC (V8 protease) is a serine proteinase. Endoproteinase GluC is able to hydrolyze some serpins and all classes of mammalian immunoglobulins .
    Endoproteinase Glu-C
  • HY-104074S
    Pocapavir-d3

    SCH-48973-d3; V-073-d3

    		 Isotope-Labeled Compounds Enterovirus Others
    Pocapavir-d3 (SCH-48973-d3; V-073-d3) is the deuterium labeled Pocapavir (HY-104074) . Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .
    Pocapavir-d3
  • HY-19381
    WAY-151932

    VNA-932; WAY-VNA 932

    		 Vasopressin Receptor Metabolic Disease Endocrinology
    WAY-151932 is a vasopressin V2-receptor agonist with IC50 of 80.3 nM and 778 nM in human-V2 binding and V1a binding assay.
    WAY-151932
  • HY-16732
    Tradipitant

    VLY-686; LY686017

    		 Neurokinin Receptor Neurological Disease Endocrinology
    Tradipitant (VLY-686) is a neurokinin-1 (NK-1) antagonist.
    Tradipitant
  • HY-P5213
    Vasopressin Dimer (parallel) (TFA)

    		Vasopressin Receptor Oxytocin Receptor Endocrinology
    Vasopressin Dimer (parallel) TFA is a parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (parallel) TFA can activate four G protein-coupled receptors, V1aR, V1bR, V2R, and OTR .
    Vasopressin Dimer (parallel) (TFA)
  • HY-P2657
    Verucopeptin

    		HIF/HIF Prolyl-Hydroxylase Proton Pump Endogenous Metabolite Cancer
    Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.
    Verucopeptin
  • HY-P5214
    Vasopressin Dimer (anti-parallel) (TFA)

    		Vasopressin Receptor Oxytocin Receptor Endocrinology
    Vasopressin Dimer (anti-parallel) TFA is an anti-parallel dimer of Vasopressin (HY-B1811). Vasopressin Dimer (anti-parallel) TFA can activate four G protein-coupled receptors, V1aR, V1bR, V2R, and OTR .
    Vasopressin Dimer (anti-parallel) (TFA)
  • HY-14887
    Fedovapagon

    VA106483

    		 Vasopressin Receptor Metabolic Disease
    Fedovapagon (VA106483) is a selective and orally active vasopressin V2 receptor (V2R) agonist with an EC50 of 24 nM. Fedovapagon can be used in the research of nocturia .
    Fedovapagon
  • HY-114507
    Flumioxazin

    Sumisoya; V-53482

    		 Herbicide Others
    Flumioxazin (Sumisoya) is an herbicide for use in soybean and peanut. Flumioxazin inhibits the enzyme protoporphyrinogen oxidase . Flumioxazin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Flumioxazin
  • HY-14185
    Lixivaptan
    2 Publications Verification

    VPA-985; WAY-VPA 985

    		 Vasopressin Receptor Cardiovascular Disease Endocrinology
    Lixivaptan (VPA-985, WAY-VPA 985) is an orally active and selective vasopressin receptor V2 antagonist, with IC50 values of 1.2 and 2.3 nM for human and rat V2, respectively.
    Lixivaptan
  • HY-N8351
    Vobtusine

    NSC 180540; Vobtusin

    		 Apoptosis Others
    Vobtusine is an alkaloid that has been found in V. africana leaves.
    Vobtusine
  • HY-101978
    Ciforadenant
    5 Publications Verification

    CPI-444; V81444

    		 Adenosine Receptor Cancer
    Ciforadenant (CPI-444) is a potent, orally active and selective adenosine A2A receptor (A2AR) antagonist, which induces antitumor responses .
    Ciforadenant
  • HY-104074
    Pocapavir
    4 Publications Verification

    SCH-48973; V-073

    		 Enterovirus Infection
    Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .
    Pocapavir
  • HY-N5148
    Vaccarin E

    		Others Others
    Vaccarin E is a natural C-glycosylflavone that could be isolated from V. hispanica .
    Vaccarin E
  • HY-P1809
    Velmupressin

    c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2

    		 Vasopressin Receptor Metabolic Disease
    Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.07 and 0.02 nM for hV2R and rV2R, respectively .
    Velmupressin
  • HY-P1809A
    Velmupressin acetate

    c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate

    		 Vasopressin Receptor Metabolic Disease
    Velmupressin (c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2) acetate is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.07 and 0.02 nM for hV2R and rV2R, respectively .
    Velmupressin acetate
  • HY-114507R
    Flumioxazin (Standard)

    Sumisoya (Standard); V-53482 (Standard)

    		 Herbicide Reference Standards Others
    Flumioxazin (Standard) is the analytical standard of Flumioxazin. This product is intended for research and analytical applications. Flumioxazin (Sumisoya) is an herbicide for use in soybean and peanut. Flumioxazin inhibits the enzyme protoporphyrinogen oxidase . Flumioxazin is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Flumioxazin (Standard)
  • HY-149380
    Vem-L-Cy5

    		Raf Cancer
    Vem-L-Cy5 (compound 3)，modified with the NIR fluorophore cyanine-5 (Cy5)，is a Vemurafenib (HY-12057)-based inhibitor of BRAF. Vem-L-Cy5 targets to BRAF V600E，and also inhibits MEK phosphorylation. Vem-L-Cy5 has cell permeability，and inhibits cell growth of many types of cancer .
    Vem-L-Cy5
  • HY-P4109
    vMIP-II (1-21)

    NT21MP; V1 peptide

    		 CXCR Inflammation/Immunology Cancer
    vMIP-II (1-21) (NT21MP) is an inhibitor of CXCR4. vMIP-II (1-21) interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) .
    vMIP-II (1-21)
  • HY-P99040
    Onvatilimab

    JNJ-61610588; CI-8993; VSTB112

    		 VISTA Cancer
    Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research .
    Onvatilimab
  • HY-15958
    VBY-825
    1 Publications Verification

    		 Cathepsin Inflammation/Immunology Cancer
    VBY-825 is an orally available novel reversible cathepsin inhibitor that has high inhibitory potency against cathepsin B, L, S and V, and possesses anti-tumor, anti-inflammatory and analgesic effects .
    VBY-825
  • HY-P4994
    Val9-Oxytocin

    		Vasopressin Receptor Cardiovascular Disease
    Val9-Oxytocin is a full antagonist of vasopressin (V1a) receptor. Val9-Oxytocin is an analog of Oxytocin (HY-17571A) in which changing Gly9 to Val9 .
    Val9-Oxytocin
  • HY-12057
    Vemurafenib
    80+ Cited Publications

    PLX4032; RG7204; RO5185426

    		 Raf Autophagy Cancer
    Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAF V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
    Vemurafenib
  • HY-P4109A
    vMIP-II (1-21) TFA

    NT21MP TFA; V1 peptide TFA

    		 CXCR Inflammation/Immunology Cancer
    vMIP-II (1-21) (NT21MP) TFA is an inhibitor of CXCR4. vMIP-II (1-21) TFA interacts broadly with CC and CXC chemokine receptors. vMIP-II (1-21) TFA inhibits CXCR4 by competing with 125I-SDF-1R for binding sites (IC50=190 nM) .
    vMIP-II (1-21) TFA
  • HY-126076A
    VPC-80051

    		DNA/RNA Synthesis Cancer
    VPC-80051 is an inhibitor of hnRNP A1 splicing activity. VPC-80051 directly interacts with hnRNP A1 RBD and reduces AR-V7 messenger levels in 22Rv1 CRPC cell line. VPC-80051 can be used in prostate cancer research .
    VPC-80051
  • HY-12057R
    Vemurafenib (Standard)

    		Raf Autophagy Cancer
    Vemurafenib (Standard) is the analytical standard of Vemurafenib. This product is intended for research and analytical applications. Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAF V600E and c-RAF-1, respectively . Vemurafenib induces cell autophagy .
    Vemurafenib (Standard)
  • HY-138697
    S65487

    VOB560

    		 Bcl-2 Family Apoptosis Cancer
    S65487 (VOB560), a potent and selective BCL-2 inhibitor, is a proagent of S55746. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 induces apoptosis and has anticaner activities .
    S65487
  • HY-138697B
    S65487 hydrochloride

    VOB560 hydrochloride

    		 Bcl-2 Family Apoptosis Cancer
    S65487 (VOB560) hydrochloride, a potent and selective Bcl-2 inhibitor, is a proagent of S55746. S65487 hydrochloride is also active on BCL-2 mutations, such as G101V and D103Y. S65487 hydrochloride has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 hydrochloride induces apoptosis and has anticaner activities .
    S65487 hydrochloride
  • HY-155971
    VISTA-IN-2

    		Autophagy Inflammation/Immunology Cancer
    VISTA-IN-2 (Compound 1) is an inhibitor of V-domain Ig suppressor of T-cell activation (VISTA). VISTA-IN-2 induces VISTA degradation in cells through an autophagic mechanism. VISTA-IN-2 rescues VISTA-mediated immunosuppression, and enhances antitumor activity of immune cells. VISTA-IN-2 also activates the antitumor immunity and inhibits tumor growth in a CT26 mouse model .
    VISTA-IN-2
  • HY-146492
    VEGFR-2/BRAF-IN-2

    		VEGFR Raf Apoptosis Cancer
    VEGFR-2/BRAF-IN-2 (Compound 4a) is a dual VEGFR-2 and BRAF kinases inhibitor with IC50 values of 0.111, 0.089 and 0.071 µM against VEGFR-2, BRAF V600E and BRAF WT, respectively. VEGFR-2/BRAF-IN-2 induces apoptosis and arrests the cell cycle mainly in the G1 phase .
    VEGFR-2/BRAF-IN-2
  • HY-138697A
    S65487 sulfate

    VOB560 sulfate

    		 Bcl-2 Family Apoptosis Cancer
    S65487 (VOB560) sulfate, a potent and selective Bcl-2 inhibitor, is a proagent of S55746. S65487 sulfate is also active on BCL-2 mutations, such as G101V and D103Y. S65487 sulfate has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 sulfate induces apoptosis and has anticaner activities .
    S65487 sulfate
  • HY-147291
    VPC-70063

    		c-Myc PARP Apoptosis Cancer
    VPC-70063 is a potent Myc-Max inhibitor with an IC50 value of 8.9 μM for Myc-Max transcriptional activity inhibition. VPC-70063 reduces UBE2C promotor activity and AR-V7 levels, and induces PARP cleavage. VPC-70063 induces apoptosis and blocks Myc-Max interactions with DNA. VPC-70063 can be used for researching anticancer .
    VPC-70063
  • HY-146491
    VEGFR-2/BRAF-IN-1

    		VEGFR Raf Apoptosis Cancer
    VEGFR-2/BRAF-IN-1 (Compound 4b) is a dual VEGFR-2 and BRAF kinases inhibitor with IC50 values of 0.049, 0.063 and 0.005 µM against VEGFR-2, BRAF V600E and BRAF WT, respectively. VEGFR-2/BRAF-IN-1 induces apoptosis and arrests the cell cycle mainly in the G1/S phase .
    VEGFR-2/BRAF-IN-1
  • HY-117669
    VPC-14228

    		Androgen Receptor Cancer
    VPC-14228 is an inhibitor that selectively targets androgen receptor DNA binding domain (AR-DBD). VPC-14228 inhibits the interaction between AR and DNA, thereby blocking AR-mediated transcriptional activation. VPC-14228 does not rely on nuclear localization inhibition, but rather inhibits the activity of full-length AR and splice variant AR-V7 by interfering with AR binding to chromatin. And VPC-14228 has high selectivity for other nuclear receptors such as ER and PR. VPC-14228 can be used in the study of prostate cancer [2].
    VPC-14228

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: